Nasdaq · CIK 0002075320
PLYX Polaryx Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Feb 20, 2026. Close $2.00 on Oct 9, 2026, +7% from the 52-week low and -94% from the high.
Polaryx Therapeutics, Inc. (PLYX) has 1 SEC Form 4 filing on file from 1 insider, the latest filed on Feb 20, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at PLYX. The newest: G. Michael Landis (Chief Financial Officer) bought $7,991 of stock on Feb 18, 2026, filed Feb 20, 2026, scored 22 (weak).
PLYX closed at $2.00 on Oct 9, 2026, 7% above its 52-week low and 94% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Polaryx Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | G. Michael Landis Chief Financial Officer buy | $7,991 2,867 shares | +1% | - |
Transactions
Every row filed, 1 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | G. Michael Landis Chief Financial Officer | POpen-market purchase Common Stock | +2,867 | $2.79 | $7,991 | 228,225 | Feb 20, 2026 |
Questions about PLYX
Answered from the filings on this page, as of the latest one.
Are insiders buying PLYX?
No. In the last 90 days no insider at Polaryx Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade PLYX on the open market?
G. Michael Landis (Chief Financial Officer) bought $7,991 of PLYX on Feb 18, 2026 and filed the Form 4 on Feb 20, 2026. InsiderTell scored 22 (weak).
How many insiders file Form 4 at Polaryx Therapeutics, Inc.?
1 person has filed a Form 4 at Polaryx Therapeutics, Inc., among them G. Michael Landis (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.